Work

Baseline Age Disparities Across GLP ‐1 Receptor Agonist–Based Trials

Year: 2026

Type: article

Abstract: To the Editor, Glucagon-like peptide-1 receptor agonist (GLP-1 RA)-based therapies now span indications from glycemic control to weight management, and cardiovascular and renal risk reduction [1].As trials have progressed along this translational arc, the enrolled populations may differ substantially.We examined whether

Source: Journal of Diabetes

DOI: 10.1111/1753-0407.70283

Authors: Wenjia Yang, Wei Zhao, Xiaoling Cai, Linong Ji

Institution: Peking University People's Hospital

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,000